Home » Stocks » CRBP

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Stock Price: $1.74 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.72 -0.02 (-1.15%) Jan 15, 7:59 PM
Market Cap 146.22M
Revenue (ttm) 5.85M
Net Income (ttm) -129.24M
Shares Out 81.88M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.74
Previous Close $1.74
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.80
Day's Range 1.60 - 1.86
Day's Volume 11,879,263
52-Week Range 0.94 - 9.38

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 4 days ago

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zacks Investment Research - 6 days ago

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

InvestorPlace - 1 month ago

Corbus Pharma (CRBP) is seeing massive gains for CRBP stock on Tuesday despite a lack of recent news from the pharmaceuticals company. The post Corbus Pharma: 8 Things for CRBP Stock Investors...

GlobeNewsWire - 2 months ago

Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

Seeking Alpha - 2 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

Corbus Pharmaceuticals Holdings, Inc.'s (CRBP) CEO Yuval Cohen On Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...

Benzinga - 2 months ago

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.6% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 34.37% year over year to ($...

GlobeNewsWire - 2 months ago

Norwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

Benzinga - 2 months ago

On Tuesday, November 10, Corbus Pharmaceuticals (NASDAQ: CRBP) will release its latest earnings report. Benzinga's outlook for Corbus Pharmaceuticals is included in the following report.

GlobeNewsWire - 2 months ago

Norwood, MA, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

GlobeNewsWire - 2 months ago

Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

Zacks Investment Research - 2 months ago

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

Norwood, MA, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

GlobeNewsWire - 2 months ago

Norwood, MA, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

GlobeNewsWire - 3 months ago

Norwood, MA, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

Zacks Investment Research - 3 months ago

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

GlobeNewsWire - 3 months ago

Norwood, MA, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transforma...

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Benzinga - 4 months ago

Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) shares were plummeting hard Tuesday following an adverse clinical data readout.

The Motley Fool - 4 months ago

A late-stage clinical failure is weighing heavily on the biotech's stock today.

24/7 Wall Street - 4 months ago

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) has reported that its systemic sclerosis study failed to reach the endpoints, and investors were not pleased.

GlobeNewsWire - 4 months ago

Norwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfo...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Seeking Alpha - 5 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Norwood, MA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 5 months ago

Norwood, MA, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 5 months ago

Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 5 months ago

Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 5 months ago

Norwood, MA, July 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

Seeking Alpha - 5 months ago

After 6 Years Corbus Shareholders Face The Ultimate Milestone: The Imminent Release Of Lenabasum's Phase 3 Data

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

The Motley Fool - 6 months ago

What’s the choice between these U.K and U.S. biotech-cannabis companies?

Other stocks mentioned: GWPH
GlobeNewsWire - 6 months ago

Norwood, MA, July 08, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 6 months ago

Norwood, MA, June 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 6 months ago

Norwood, MA, June 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

The Motley Fool - 7 months ago

Here are seven straightforward steps to help you invest in high-growth -- but high-risk -- marijuana stocks.

Other stocks mentioned: ACB, APHA, CARA, CGC, CRON, GWPH, HEXO, MJ, OGI, SMG, TLRY
Zacks Investment Research - 7 months ago

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Zacks Investment Research - 7 months ago

Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 7 months ago

Norwood, MA, June 01, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfor...

GlobeNewsWire - 7 months ago

Norwood, MA, May 27, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transform...

GlobeNewsWire - 7 months ago

Norwood, MA, May 22, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transform...

Zacks Investment Research - 8 months ago

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Seeking Alpha - 8 months ago

Corbus Pharmaceuticals Holdings, Inc. (CRBP) CEO Yuval Cohen on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...

Benzinga - 8 months ago

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell 1.3% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 8 months ago

Norwood, MA, May 11, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transform...

GlobeNewsWire - 8 months ago

Norwood, MA, April 29, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transfo...

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Yuval Cohen
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
CRBP
Full Company Profile

Financial Performance

In 2019, CRBP's revenue was $36.14 million, an increase of 649.51% compared to the previous year's $4.82 million. Losses were -$71.45 million, 28.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRBP stock is "Hold." The 12-month stock price forecast is 1.88, which is an increase of 8.05% from the latest price.

Price Target
$1.88
(8.05% upside)
Analyst Consensus: Hold